- Home
- ARVN vs TRC Comparison
ARVN vs TRC Comparison
Compare ARVN & TRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | TRC |
|---|---|---|
| Founded | 2015 | 1843 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 519.6M |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ARVN | TRC |
|---|---|---|
| Price | $8.95 | $19.40 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 858.9K | 77.4K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $262,600,000.00 | $37,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1,963.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.06 | $15.31 |
| 52 Week High | $14.22 | $21.31 |
Technical Indicators
Market Signals| Indicator | ARVN | TRC |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 49.12 |
| Support Level | $8.72 | $19.34 |
| Resistance Level | $10.18 | $19.79 |
| Average True Range (ATR) | 0.47 | 0.47 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 28.82 | 42.70 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.